Presentation is loading. Please wait.

Presentation is loading. Please wait.

HYPERBILIRUBINEMIA and its TREATMENT By: Evgenia Klourfeld Candy Pletzer

Similar presentations


Presentation on theme: "HYPERBILIRUBINEMIA and its TREATMENT By: Evgenia Klourfeld Candy Pletzer"— Presentation transcript:

1 HYPERBILIRUBINEMIA and its TREATMENT By: Evgenia Klourfeld Candy Pletzer Jane Lui Jan. 27, 2004 PHM 226, Example Instructor: Dr. Jeffrey Henderson

2 What is Bilirubin? Is a bile pigment Is lipid soluble Is a product of heme metabolism

3 Heme Metabolism Hemoglobin – 80% Myoglobin Cytochrome P450s Hemoproteins Macrophage of the reticuloendothelial system Heme Heme Oxygenase Biliverdin Biliverdin Reductase Bilirubin Blood O2O2 Fe 3+ + CO NADPH + H + NADP+ Modified from Ganon, W.F. Review of Medical Physiology, (6 th ed.).

4 The Fate of Bilirubin… Alb = albuminB = bilirubinGST = glutathione-S-transferase UDPGA = uridine diphosphoglucuronic acid;CB = conjugated bilirubin UGT1A1 = UDP-glucuronosyltransferase 1A1 MRP2 = Multi-drug Resistance Protein 2 Adapted from Harrison’s 15 th Ed. “Principles of Internal Medicine”, MRP2B + GST CB Plasma Hepatic Cell BileAlbB Alb ? :GSTB sER B + UDPGA UGT1A1

5 Bilirubin Excretion Intestines Liver BCB CB B Urobilinogen B-glucoronidase bacteria Bile Enterohepatic circulation ox Urobilin Stercobilin Stercobilingogen feces

6 Bilirubin Excretion Intestines Liver BCB CB B Urobilinogen B-glucoronidase bacteria Bile Enterohepatic circulation Kidney Urobilin ox Urobilinogen Urobilin Stercobilin Stercobilingogen feces Urine ox

7 Hyperbilirubinemia Interferences at any one of the points of bilirubin processing described above can lead to a condition known as HYPERBILIRUBINEMIA. Interferences at any one of the points of bilirubin processing described above can lead to a condition known as HYPERBILIRUBINEMIA. As the name implies this disease is characterized by abnormally elevated levels of bilirubin in the blood. As the name implies this disease is characterized by abnormally elevated levels of bilirubin in the blood.

8 SYMPTOMS o Yellowing of the skin, scleras (white of the eye), and mucous membranes (jaundice) o Detectable when total plasma bilirubin levels exceed 2mg/100mL AHHH!!! I have symptoms of hyperbilirubinemia!!!

9 Causes : 1. Increased bilirubin production 2. Reduced bilirubin uptake by hepatic cells 3. Disrupted intracellular conjugation 4. Disrupted secretion of bilirubin into bile canaliculi 5. Intra/extra-hepatic bile duct obstruction Lead to increases in free (unconj.) bilirubin Result in rise in conj. bilirubin levels

10 1)INCREASED BILIRUBIN PRODUCTION (unconj. Hyperbilirubinemia)  Hemolysis  Increased destruction of RBCs  eg sickle cell anemia, thalassemia  Drastic increase in the amount of bilirubin produced  Unconj. bilirubin levels rise due to liver’s inability to catch up to the increased rate of RBC destruction  Prolonged hemolysis may lead to precipitation of bilirubin salts in the gall bladder and biliary network  result in formation of gallstones and conditions such as cholecystitis and biliary obstruction  Other  Degradation of Hb originating from areas of tissue infarctions and hematomas  Ineffective erythropoiesis

11 2)DECREASED HEPATIC UPTAKE (unconj. Hyperbilirubinemia)  Several drugs have been reported to inhibit bilirubin uptake by the liver  e.g. novobiocin, flavopiridol Bile MRP2 B + GST CB Plasma Hepatic cell Alb B :GST B sER B + UDPGA UGT1A1

12 3) DISRUPTED INTRACELLULAR CONJUGATION (unconj. Hyperbilirubinemia)  Neonatal jaundice  occurs in 50% of newborns  fetal bilirubin is eliminated by mother’s liver  causes:  hepatic mechanisms are not fully developed resulting in decreased ability to conjugate bilirubin  rate of bilirubin production is increased due to shorter lifespan of RBCs  Acquired disorders  hepatitis, cirrhosis  impaired liver function

13 3) DISRUPTED INTRACELLULAR CONJUGATION (unconj. Hyperbilirubinemia) Crigler-Najjar Syndrome, Type I (CN-I)  Crigler-Najjar Syndrome, Type I (CN-I) recessive allele; mutation-induced loss of conjugating ability in the critical enzyme glucuronosyltransferase  CN-II greatly reduced but detectable glucuronosyltransferase activity due to mutation (predominantly recessive); enzymatic activity can be induced by drugs  Gilbert’s Syndrome glucuronosyl transferase activity reduced to 10-30% of normal; also accompanied by defective bilirubin uptake mechanism Bile MRP2B + GST CB Plasma Hepatic cell Alb B :GSTB sER B + UDPGA UGT1A1

14 4) DISRUPTED SECRETION OF BILIRUBIN INTO BILE CANALICULI (conj. Hyperbilirubinemia)  Dubin–Johnson Syndrome  mild conj. hyperbilirubinemia, but can increase with concurrent illness, pregnancy, and use of oral contraceptives; otherwise asymptomatic  Inability of hepatocytes to secrete CB after it has formed  Due to mutation in the MRP2 gene (autosomal recessive trait)  Rotor Syndrome  Autosomal recessive condition characterized by increased total bilirubin levels due to a rise in CB  Caused by a defect in transport of bilirubin into bile Bile MRP2B + GST CB Plasma Hepatic cell Alb B :GSTB sER B + UDPGA UGT1A1

15 5) Intra/extra-hepatic bile duct obstruction  Intra-hepatic Obstruction of bile canaliculi, bile ductules or hepatic ducts  Extra-hepatic Obstruction of cystic duct or common bile duct Cholecystitis  Obstruction causes backup and reabsorption of CB which results in increased blood levels of CB

16 Treatment & Therapeutic Considerations **PHOTOTHERAPY**  Through absorption of the wavelengths at the blue end of the spectrum (blue, green and white light), bilirubin is converted into water-soluble photoisomers. This transformation enhances the molecule’s excretion into bile without conjugation. PHENOBARBITAL  This drug is not approved by FDA for use in neither adult nor pediatric hyperbilirubinemia patients, due to possibility of significant systemic side-effects.  Exact pathway is not known, but it is believed to act as an inducing agent on UDP- glucuronosyltransferase, thereby improving conjugation of bilirubin and its excretion. ALBUMIN  A 25% infusion can be used in treating hyperbilirubinemia (esp. due to hemolytic disease).  It is used in conjunction with exchange transfusion to bind bilirubin, enhancing its removal. CLOFIBRATE (ATROMID-S)  This drug has been shown to reduce bilirubin levels via an unknown mechanism.  Clofibrate is also associated with increased risk of developing cholelithiasis, cholecystitis, as well as functional liver abnormalities, which can worsen hyperbilirubinemia. **PERCUTANEOUS TRANSHEPATIC CHOLANGIOGRAPHY**  Allows extraction of stones and thus removal of the source of obstruction when present.

17 ADVERSE THERAPEUTIC EFFECTS  Flavopiridol – can induce hyperbilirubinemia. It shares the glucuronidation pathway that is involved in bilirubin conjugation, effectively reducing the amount of bilirubin that can be processed by the hepatic cells at any given time.  Novobiocin – inhibits the UDP-glucuronosyltransferase activity, leading to hyperbilirubinemia.  Valspodar – causes an increase in bilirubin levels by P- glycoproteins in the biliary canaliculi, thus interfering with bilirubin transport.

18 REFERENCES 1. Braunwald, E., Fauci, A.S., Kasper, D.L. Harrison’s Principles of Internal Medicine, (15 th ed.). McGraw-Hill Medical Publishing Division: New York, CPS Compendium of Pharmaceuticals and Specialties, (32 nd ed.). Canadian Pharmaceutical Association: Ottawa, Ganong, W.F. Review of Medical Physiology, (6 th ed.). Lange Medical Publications: Los Altos, MICROMEDEX. 5. Mims, L., Gooden, D.S. Phototherapy for neonatal hyperbilirubinemia: a dose response relationship. Phys. Med. Biol. 1974;19:


Download ppt "HYPERBILIRUBINEMIA and its TREATMENT By: Evgenia Klourfeld Candy Pletzer"

Similar presentations


Ads by Google